1460882556-0e4b764a-e105-4424-a5a3-257a77fe97f8

1. Group A streptogramin derivative of the formula:
9
in which
R1 represents a halogen atom or an azido or thiocyanato radical,
R2 represents a hydrogen atom or a methyl or ethyl radical,
R3 represents a hydrogen atom, or the residue of an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, and
the bond – – – represents a single bond (stereochemistry 27R) or a double bond,
as well as its salts when they exist.
2. Group A streptogramin derivative according to claim 1, characterized in that the residue R3 of an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted is a radical R3CO for which R3 is phenyl or phenylalkyl which are unsubstituted or which are substituted on the phenyl radical with one or more radicals chosen from alkyl, optionally carrying a radical NRR in which the radicals R and R, which are identical or different, may be hydrogen atoms or alkyl radicals which can form together with the nitrogen atom to which they are attached a 3- to 8-membered saturated or unsaturated heterocyclyl radical optionally comprising another heteroatom chosen from oxygen, sulfur or nitrogen, it being possible for the said heterocycle itself to be substituted with one or more radicals (alkyl, hydroxyalkyl, alkyloxyalkyl, alkyloxycarbonylalkyl, aryl, heterocyclyl, heterocyclylalkyl, which are saturated or unsaturated and have 3 to 8 members, or CH2CONRR), or alternatively R andor R may be a hydroxyalkyl radical, a phenyl radical, a 3- to 8-membered saturated or unsaturated heterocyclylalkyl radical, a radical CONRR for which NRR is as defined above, or alkyl or acyl radicals which are substituted with NRR which is as defined above, or alternatively R3 may be chosen from phenyl or phenylalkyl radicals which are substituted on the phenyl radical with one or more radicals chosen from alkyl, which may be substituted with an alkyloxy or alkylthio radical optionally carrying themselves a carboxyl radical or a radical NRR as defined above, or chosen from acyloxy which may be substituted with NRR as defined above, or alternatively R3 may be chosen from alkyl or cycloalkyl radicals which are optionally substituted with a carboxyl radical, a carboxyalkyldisulfanyl radical or with a radical NRR, CH2NRR, or CONRR, or with an alkyloxycarbonyl, alkyloxy or alkyldisulfanyl radical which are optionally substituted with NRR or CONRR for which NRR is as defined above, or alternatively R3 may be chosen from 3- to 8-membered saturated or unsaturated heterocyclyl radicals which are optionally substituted with alkyl or acyl which are themselves optionally substituted with NRR.
3. Group A streptogramin derivative according to either of claims 1 and 2, characterized in that:
R1 represents a fluorine, chlorine, bromine or iodine atom or an azido or thiocyanato radical,
R2 represents a methyl radical,
R3 represents a hydrogen atom or a radical R3CO for which R3 is phenyl or phenylalkyl which are substituted or unsubstituted on the phenyl radical with one or more radicals chosen from alkyl, optionally carrying a radical NRR in which the radicals R and R, which are identical or different, may be hydrogen atoms or alkyl radicals which can form together with the nitrogen atom to which they are attached a 3- to 8-membered saturated or unsaturated heterocyclyl radical optionally comprising another hetero atom chosen from oxygen, sulfur or nitrogen, it being possible for the said heterocycle itself to be substituted with one or more radicals (alkyl, hydroxyalkyl, alkyloxyalkyl, alkyloxycarbonylalkyl, aryl, 3- to 8-membered saturated or unsaturated heterocyclyl or heterocyclylalkyl, or CH2CONRR), or alternatively R andor R may be a radical hydroxyalkyl, phenyl, 3- to 8-membered saturated or unsaturated heterocyclylalkyl, CONRR for which NRR is as defined above, or alkyl or acyl which are substituted with NRR as defined above, or alternatively R3 may be a phenyl radical substituted with one or more radicals chosen from alkyl, which may be substituted with an alkyloxy or alkylthio radical themselves optionally carrying a carboxyl radical or a radical NRR as defined above, or chosen from acyloxy which may be substituted with NRR as defined above, or alternatively R3 may be chosen from alkyl or cycloalkyl radicals which are optionally substituted with a carboxyl or carboxyalkyl-disulfanyl radical or with a radical NRR, CH2NRR or CONRR, or with an alkyloxycarbonyl, alkyloxy or alkyldisulfanyl radical which are optionally substituted with NRR or CONRR for which NRR is as defined above, or alternatively R3 may be chosen from 3- to 8-membered saturated or unsaturated heterocyclyl radicals which are optionally substituted with alkyl or acyl which are themselves optionally substituted with NRR, it being understood that the heterocycles are chosen from pyrrolidinyl, imidazolyl, pyridyl, piperidinyl, piperazinyl or morpholinyl, and
the bond – – – represents a single bond (stereochemistry 27R) or a double bond, as well as their salts when they exist.
4. Group A streptogramin derivative according to one of claims 1 to 3, characterized in that it is (16R)-16-deoxo-16-fluoropristinamycin IIB.
5. Group A streptogramin derivative according to one of claims 1 to 3, characterized in that it is (16R)-16-deoxo-16-thiocyanatopristinamycin IIB.
6. Group A streptogramin derivative according to one of claims 1 to 3, characterized in that it is (16R)-16-deoxo-16-chloropristinamycin IIB.
7. Group A streptogramin derivative according to one of claims 1 to 3, characterized in that it is (16R)-16-azido-16-deoxopristinamycin IIB.
8. Group A streptogramin derivative according to one of claims 1 to 3, characterized in that it is (16R)-16-deoxo-16-fluoropristinamycin IIA.
9. Process for preparing a group A streptogramin derivative according to claim 1, characterized in that there is halogenated, in that there is converted to an azide or in that there is converted to a thiocyanate, a streptogramin derivative of general formula:
10
in which R2 is as defined above, the bond – – – represents a single bond (stereochemistry 27R) or a double bond, and in which the hydroxyl function at the 14-position has been previously protected, followed by the removal of the protecting radical and where appropriate, in order to obtain a group A streptogramin derivative according to claim 1 or 2, for which R3 is other than a hydrogen atom, introduction of the aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester residue which may be substituted (R3), and optionally conversion to a salt when they exist.
10. Process according to claim 9, characterized in that the procedure is carried out in the presence of an aminosulfur trifluoride or in the presence of sulfur tetrafluoride, by means of a reagent such as a tetraalkylammonium, trialkylbenzylammonium or trialkylphenylammonium halide, azide or thiocyanate or by means of an alkali metal halide, azide or thiocyanate optionally supplemented with a crown ether.
11. Process according to claim 9, characterized in that the procedure is carried out, for the fluorination, by the action of a fluorinating agent chosen from a sulfur fluoride, hexafluoropropyldiethylamine or N-(2chloro-1,1,2-trifluoro-ethyl)diethylamine.
12. Process according to one of claims 9, 10 or 11, characterized in that, where appropriate, the esterification is carried out by any known method which does not alter the rest of the molecule.
13. Process according to one of claims 9, 10 or 12, characterized in that the aminosulfur trifluoride may be chosen from diethylaminosulfur trifluoride, bis-(2-methoxyethyl)aminosulfur trifluoride or morpholinosulfur trifluoride.
14. Pharmaceutical composition comprising a group A streptogramin derivative according to claim 1 or 2, in the pure state or in the form of a combination with at least one group B streptogramin derivative, where appropriate in the form of a salt, andor in the form of a combination with one or more compatible and pharmaceutically acceptable diluents or adjuvants.
15. Pharmaceutical composition according to claim 14, characterized in that the group B streptogramin derivative is chosen from the natural components: pristinamycin IA, pristinamycin IB, pristinamycin IC, pristinamycin ID, pristinamycin IE, pristinamycin IF, pristinamycin IG, virginiamycin S1, S3 or S4, vemamycin B or C, etamycin or from the semisynthetic derivatives of general formula:
11
in which,
1. Rb, Rc, Re and Rf are hydrogen atoms, Rd is a hydrogen atom or a dimethylamino radical, and Ra is a radical of structure CH2Ra for which Ra is 3-pyrrolidinylthio or 3- or 4-piperidylthio which may be substituted with alkyl, or alkylthio substituted with 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino (itself optionally substituted with mercapto or dialkylamino), or substituted with 1 or 2 optionally substituted piperazine rings, morpholino, thiomorpholino, piperidino, 1-pyrrolidinyl, 2-, 3- or 4-piperidyl or 2- or 3-pyrrolidinyl (which may be substituted with alkyl), or alternatively Ra is a radical of structure CHRa for which Ra is 3-pyrrolidinylamino, 3- or 4-piperidylamino, 3-pyrrolidinyloxy, 3- or 4-piperidyloxy, 3-pyrrolidinylthio, 3- or 4-piperidylthio which may be substituted with alkyl, or Ra is alkylamino, alkyloxy or alkylthio substituted with 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino (itself optionally substituted with dialkylamino), or with trialkylammonio, 4- or 5-imidazolyl, or with 1 or 2 optionally substituted piperazine rings, morpholino, thiomorpholino, piperidino, 1-pyrrolidinyl, 2-, 3- or 4-piperidyl or 2- or 3-pyrrolidinyl (which may be substituted with alkyl), or Ra is a 3- or 4quinuclidinylthiomethyl radical, or alternatively
2. Ra is a hydrogen atom and
a) either Rb, Re and Rf are hydrogen atoms, Rd is a radical NHCH3 or N(CH3)2 and Rc is a chlorine or bromine atom, or represents an alkenyl radical containing 3 to 5 carbon atoms if Rd is N(CH3)2,
b) or Rb, Rd, Re and Rf represent a hydrogen atom and Rc is a halogen, or an aminomonoalkyl, aminodialkyl, alkyloxy, trifluoromethyloxy, thioalkyl, C1 to C3 alkyl or trihalomethyl radical,
c) or Rb, Rc, Re and Rf represent a hydrogen atom and Rd is a halogen, or an ethylamino, diethylamino or methylethylamino, alkyloxy or trifluoromethyloxy, thioalkyl, C1 to C6 alkyl, aryl or trihalomethyl radical,
d) or Rb, Re and Rf represent a hydrogen atom and Rc is halogen or an aminomonoalkyl or aminodialkyl, alkyloxy or trifluoromethyloxy, thioalkyl or C1 to C3 alkyl radical, and Rd is halogen or an amino, aminomonoalkyl or aminodialkyl, alkyloxy or trifluoromethyloxy, thioalkyl, C1 to C6 alkyl or trihalomethyl radical,
e) or Rc, Re and Rf represent a hydrogen atom and Rb and Rd represent a methyl radical;
or alternatively from the semisynthetic derivatives of general formula:
12
in which
Y is a nitrogen atom or a radical CR3,
R1 is a hydrogen atom, an alkyl radical (1 to 8 carbons), an alkenyl radical (2 to 8 carbons), a cycloalkyl radical (3 to 8 carbons), a saturated or unsaturated heterocyclyl radical (3 to 8 members), a phenyl radical, a phenyl radical which is substituted with one or more halogen atoms or hydroxyl, alkyl, alkyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino or dialkylaamino radicals or a radical NRR, it being possible for R and R, which are identical or different, to be hydrogen atoms or alkyl radicals (1 to 3 carbons) or to form together with the nitrogen atom to which they are attached a 3- to 8-membered heterocycle optionally containing another heteroatom chosen from oxygen, sulfur or nitrogen, optionally substituted with an alkyl radical, an alkenyl radical (2 to 8 carbons), a cycloalkyl radical (3 to 6 carbons), a saturated or unsaturated heterocyclyl radical (4 to 6 members), a benzyl radical, a phenyl radical or a phenyl radical which is substituted as defined above for the definition of R1 or alternatively when Y is a radical CR3, R1 may also be halomethyl, hydroxymethyl, alkyloxymethyl, alkylthiomethyl in which the alkyl portion is optionally substituted with NRR, alkylsulfinylmethyl, alkylsulfonylmethyl, acyloxymethyl, benzoyloxymethyl, cyclopropylaminomethyl or (CH2)nNRR (n being an integer from 1 to 4 and R and R being as defined above) or alternatively if R3 is a hydrogen atom, R1 may also be formyl, carboxyl, alkyloxycarbonyl, or CONRR for which R and R are as defined above,
or alternatively when Y is a nitrogen atom, R1 may also be a radical XR for which X is an oxygen or sulfur atom, a sulfinyl or sulfonyl radical, or an NH radical and R is an alkyl radical (1 to 8 carbons), a cycloalkyl radical (3 to 6 carbons), a saturated or unsaturated heterocyclyl radical (3 to 8 members), a heterocyclylmethyl radical (3 to 8 members) in which the heterocyclyl portion is attached to the methyl radical by a carbon atom, a phenyl radical, a phenyl radical which is substituted with one or more halogen atoms or hydroxyl, alkyl, alkyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino or dialkylamino radicals or a radical (CH2)nNRR for which R and R are as defined above and n is an integer from 2 to 4, or alternatively, if X represents NH, R may also represent a hydrogen atom,

R2 is a hydrogen atom or an alkyl radical (1 to 3 carbons),
R3 is a hydrogen atom or an alkyl radical, a carboxyl radical, an alkyloxycarbonyl radical, or a carbamoyl radical of structure CONRR in which R and R are as defined above,
Ra is a methyl or ethyl radical, and
Rb, Rc and Rd have the definitions below:
1) Rb and Rc are hydrogen atoms and Rd is a hydrogen atom or a methylamino or dimethylamino radical,
2) Rb is a hydrogen atom, Rc is a hydrogen, chlorine or bromine atom, or represents an alkenyl radical (3 to 5C), and Rd is a radical NMeR for which R represents a radical alkyl, hydroxyalkyl (2 to 4C), or alkenyl (2 to 8C) which is optionally substituted with phenyl, cycloalkyl(3 to 6C)methyl, benzyl, benzyl which is substituted with one or more halogen atoms or hydroxyl, alkyl, alkyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino or dialkylamino radicals, heterocyclylmethyl or heterocyclylethyl in which the heterocyclyl portion is saturated or unsaturated and contains 5 to 6 members and one or two heteroatoms chosen from sulfur, oxygen or nitrogen optionally substituted with an alkyl radical, an alkenyl radical (2 to 8 carbons), a cycloalkyl radical (3 to 6 carbons), a saturated or unsaturated heterocyclyl radical (4 to 6 members), a phenyl radical, a phenyl radical which is substituted as defined above for the definition of R1 or a benzyl radical, or alternatively R represents a cyanomethyl radical, or CH2CORe for which either Re is ORe, Re being hydrogen, alkyl (1 to 6 carbons), alkenyl (2 to 6 carbons), benzyl or heterocyclylmethyl in which the heterocyclyl portion contains 5 to 6 members and 1 or 2 heteroatoms chosen from sulfur, oxygen or nitrogen or Re is an alkylamino radical, an alkylmethylamino radical, a heterocyclylamino radical or a heterocyclylmethylamino radical in which the heterocyclyl portion is saturated and contains 5 to 6 members and one or two heteroatoms chosen from sulfur, oxygen or nitrogen optionally substituted with an alkyl, benzyl or alkyloxycarbonyl radical,
3) Rb is a hydrogen atom, Rd is a radical NHCH3 or N(CH3)2 and Rc is a chlorine or bromine atom, or represents an alkenyl radical (3 to 5C), if Rd is N(CH3)2,
4) Rb and Rd are hydrogen atoms and Rc is a halogen atom, or an alkylamino or dialkylamino, alkyloxy, trifluoromethoxy, thioalkyl, alkyl (1 to 6C) or trihalomethyl radical,
5) Rb and Rc are hydrogen atoms and Rd is a halogen atom, or an ethylamino, diethylamino or methylethylamino, alkyloxy or trifluoromethoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl (1 to 6C), phenyl or trihalomethyl radical,
6) Rb is a hydrogen atom and Rc is a halogen atom or an alkylamino or dialkylamino, alkyloxy or trifluoromethoxy, thioalkyl or alkyl (1 to 3C) radical and Rd is a halogen atom or an amino, alkylamino or dialkylamino, alkyloxy or trifluoromethoxy, thioalkyl, alkyl (1 to 6C) or trihalomethyl radical,
7) Rc is a hydrogen atom and Rb and Rd represent a methyl radical, as well as their salts.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A dosage form, comprising a plurality of modified release doxycycline pellets, wherein each doxycycline pellet comprises:
doxycycline; and
a controlled release polymer composition disposed over the doxycycline,

wherein said dosage form comprises 60, 90, or 120 mg of doxycycline and releases less than about 15% of the doxycycline at pH 1.2, and less than 40% of the doxycycline at pH 4.5 after 60 minutes, measured under USP <711> conditions; and
wherein when the amount of doxycycline of said dosage form is 60 mg, after administration of a single dose under fasting conditions to a patient in need thereof, the average Cmax is about 80% to about 125% of about 625-1600 ngml;
or
wherein when the amount of doxycycline of said dosage form is 90 mg, after administration of a single dose under fasting conditions to a patient in need thereof, the average Cmax is about 80% to about 125% of about 940-2400 ngml;
or
wherein when the amount of doxycycline of said dosage form is 120 mg, after administration of a single dose under fasting conditions to a patient in need thereof, the average Cmax is about 80% to about 125% of about 1250-3200 ngml.
2. The dosage form of claim 1, wherein when the amount of doxycycline of said dosage form is 60 mg, after administration of a single dose to a patient in need thereof, the average AUC0-\u221e is about 80% to about 125% of about 10000-24000 ng\xb7hrml; or
wherein when the amount of doxycycline of said dosage form is 90 mg, after administration of a single dose to a patient in need thereof, the average AUC0-\u221e is about 80% to about 125% of about 15000-36500 ng\xb7hrml; or
wherein when the amount of doxycycline of said dosage form is 120 mg, after administration of a single dose to a patient in need thereof, the average AUC0-\u221e is about 80% to about 125% of about 20000-48500 ng\xb7hrml.
3. The dosage form of claim 1, wherein the doxycycline pellets comprise a doxycycline-containing core, and the controlled release polymer composition is disposed as a layer over the core.
4. The dosage form of claim 3, wherein the controlled release polymer composition comprises a blend of an enteric polymer and a water soluble polymer.
5. The dosage form of claim 4, wherein the controlled release polymer composition further comprises a plasticizer.
6. The dosage form of claim 5, wherein the controlled release polymer composition consists essentially of a blend of an enteric polymer, a water soluble polymer, and a plasticizer.
7. The dosage form of claim 4, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, poly(methacrylic acid-co-ethyl acrylate), poly(methacrylic acid-co-methyl methacrylate), poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid), hydroxypropylmethyl cellulose acetate succinate, cellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, and combinations thereof.
8. The dosage form of claim 4, wherein the water soluble polymer is selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, polyethylene glycol, polyvinyl alcohol, and combinations thereof.
9. The dosage form of claim 5, wherein the plasticizer is selected from the group consisting of citric acid esters, tartaric acid esters, glycerol, glycerol esters, phthalic acid esters, adipic acid esters, sebacic acid esters, polyethylene glycol esters, sorbitan esters, and combinations thereof.
10. The dosage form of claim 6, wherein the controlled release polymer composition consists essentially of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose, and triethyl citrate.
11. The dosage form of claim 10, wherein the ratio of hydroxypropyl methylcellulose phthalate to hydroxypropyl methylcellulose ranges from about 3.5:1 to about 6:1.
12. The dosage form of claim 3, further comprising a stabilizing coating disposed between the core and the controlled release polymer composition layer.
13. The dosage form of claim 12, wherein the stabilizing coating comprises a water soluble polymer and talc.
14. A method of treating a skin condition in a patient, comprising orally administering the dosage form of claim 1 to a patient in need thereof.
15. A method of treating a skin condition in a patient, comprising orally administering the dosage form of claim 3 to a patient in need thereof.
16. The method of claim 14, wherein said skin condition is at least one condition selected from the group consisting of: a skin infection, rosacea, acne, papules, pustules, open comedo, closed comedo, or a combination thereof.
17. The method of claim 15, wherein said skin condition is at least one condition selected from the group consisting of: a skin infection, rosacea, acne, papules, pustules, open comedo, closed comedo, or a combination thereof.
18. The method of claim 14, wherein said administering is once-per-day.
19. The method of claim 15, wherein said administering is once-per-day.
20. The dosage form of claim 1, wherein the amount of doxycycline of said dosage form is 60 mg.
21. The dosage form of claim 1, wherein the amount of doxycycline of said dosage form is 90 mg.
22. The dosage form of claim 1, wherein the amount of doxycycline of said dosage form is 120 mg.
23. The dosage form of claim 2, wherein the amount of doxycycline of said dosage form is 60 mg.
24. The dosage form of claim 2, wherein the amount of doxycycline of said dosage form is 90 mg.
25. The dosage form of claim 2, wherein the amount of doxycycline of said dosage form is 120 mg.
26. The dosage form of claim 3, wherein the controlled release polymer composition comprises a blend of an enteric polymer and a plasticizer.